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INTRODUCTION 
 
 The target of antiretroviral therapy in patients with HIV/AIDS is to 
reach a complete and durable suppression of plasma viral replication in 
order to restore or maintain the immune function and to minimize the 
development of viral drug resistance.  
 The prospects for treatment-naive people have never been better, 
with the availability of more than 20 different antiretroviral agents in 
four different classes, that has made long-term control of HIV 
replication a readily achievable outcome for the majority of HIV-infected 
patients initiating therapy in latest two years [1]. Unfortunately, the 
patients who were infected with HIV earlier have not been able to take 
advantage of the major improvements in therapy achieved with the 
HAART era. 
As consequence, a large proportion of HIV-infected patients currently in 
care are infected with resistant viruses which require expert attention to 
ensure the best possible options for treatment [2]. 
 While specific recommendations are available to treat patients 
starting antiretroviral therapy for the first time, the situation for 
treatment-experienced patients is more difficult. Each patient has 
arrived at a particular point in the treatment sequence that represents 
the accumulated effects of prior treatment choices, levels of adherence, 
drug interaction events, and specific viral characteristics [3]. 
 The success of the therapy might be due to individual patient’s 
situation, some of them able to recover to a full suppression of HIV 
replication, while in some others an immunological stabilization is the 
only long-term strategy  
Continuous viral replication during therapy leads to accumulate drug-
resistance mutations, resulting in increased viral load and a greater risk 
of disease progression. Patients with drug-resistant HIV-1 infection 
have three therapeutic options: a change to a salvage regimen with the 
aim of fully suppressing viral replication; a decision of interruption of 
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therapy; or maintenance of a partially effective regimen [4]. The first 
strategy is the best choice for patients failing their first or perhaps their 
second regimen. However, the best approach remains unclear for 
patients who have failed multiple treatment regimens and who have 
limited options for complete viral suppression.  
 The understanding of the pathogenic mechanism underlaying the 
 drug-resistant HIV-1, the clinical consequences of virological 
failure, the potential benefits and limitations of diagnostic assays, and 
the efficacy of new drugs,  is necessary in order of an effective 
management of such patients [5]. 
 An important phase for the development of new drugs is the 
dynamic research of their molecular targets. 
The antiretroviral drugs currently used, or still in phase of study, in the 
therapy of the AIDS can be classified on the bases of their targets in: 
1. Reverse transcriptase inhibition: 
a) nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs 
and NtRTIs); 
b) Non-nucleoside reverse transcriptase inhibitors (NNRTIs);   
2. Protease inhibition (PIs);   
3. Cellular fusion inhibition; 
4. Modulator of cellular receptor CD4 expression; 
5. Antagonists of the chemokine receptors 
6. integrase inhibition 
7. transcription inhibition 
8. ribonuclease H inhibition 
 
Table 1 shows the date of the antiretroviral drugs entry into clinical use. 
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Current anti-HIV drug regimens, termed Highly Active Antiretroviral 
Therapy (HAART), consist of a combination of at least three 
antiretroviral drugs, with two or more nucleotide reverse transcriptase 
inhibitors (NRTIs) being a staple of most regimens [6]. The most 
common combination given to those beginning treatment consists of 
two NRTIs combined with either an NNRTI or a "boosted" protease 
inhibitor. Ritonavir (in small doses) is the drug most commonly used to 
boost a protease inhibitor. Table 2 lists the drugs combination used in 
the treatment of HIV infection [7]. 
 
 
Table 1. Entry of antiretroviral agents into clinical use 
1987 Zidovudine 1998 Efavirenz 
1991 Didanosine  Abacavir 
1992 Zalcitabine 1999 Amprenavir 
1994 Stavudine 2000 Lopinavir 
1995 Lamivudine 2001 Tenofovir 
 Saquinavir 2003 Emtricitabine 
1996 Ritonavir  Enfuvirtide 
 Indinavir  Atazanavir 
 Nevirapine  Fos-amprenavir 
1997 Nelfinavir 2005 Tripranavir 
 Delavirdine 2006 Darunavir 
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Table 2. Drugs combination and date of their approval 
Brand Name Generic Names Approval Date 
 
Multi-class Combination Products 
Atripla efavirenz, emtricitabine and tenofovir 12-July-06 
 
Nucleoside Reverse Transcriptase Inhibitors (NRTIs) 
Combivir lamivudine and zidovudine 27-Sep-97 
Emtriva emtricitabine, FTC 02-Jul-03 
Epivir lamivudine, 3TC 17-Nov-95 
Epzicom abacavir and lamivudine 02-Aug-04 
Hivid zalcitabine, dideoxycytidine, ddC 19-Jun-92 
Retrovir zidovudine, azidothymidine, AZT, ZDV 19-Mar-87 
Trizivir abacavir, zidovudine, and lamivudine 14-Nov-00 
Truvada tenofovir disoproxil fumarate and 
emtricitabine 
02-Aug-04 
Videx EC nteric coat d didanosine, ddI EC 31-Oct-00 
Videx didanosine, dideoxyinosine, ddI 9-Oct-91 
Viread tenofovir disoproxil fumarate, TDF 26-Oct-01 
Zerit stavudine, d4T 24-Jun-94 
Ziagen abacavir sulfate, ABC 17-Dec-98 
 
Nonnucleoside Reverse Transcriptase Inhibitors (NNRTIs) 
Rescriptor delavirdine, DLV 4-Apr-97 
Sustiva efavirenz, EFV 17-Sep-98 
Viramune nevirapine, NVP 21-Jun-96 
 
Protease Inhibitors (PIs) 
Agenerase amprenavir, APV 15-Apr-99 
Aptivus tipranavir, TPV 22-Jun-05 
Crixivan indinavir, IDV, 13-Mar-96 
Fortovase saquinavir (no longer marketed) 7-Nov-97 
Invirase saquinavir mesylate, SQV 6-Dec-95 
Kaletra lopinavir and ritonavir, LPV/RTV 15-Sep-00 
Lexiva Fosamprenavir Calcium, FOS-APV 20-Oct-03 
Norvir ritonavir, RTV 1-Mar-96 
Prezista darunavir 23-Jun-06 
Reyataz atazanavir sulfate, ATV 20-Jun-03 
Viracept nelfinavir mesylate, NFV 14-Mar-97 
 
Fusion Inhibitors 
Fuzeon enfuvirtide, T-20 13-Mar-03 
 
Entry Inhibitors - CCR5 co-receptor antagonist 
Selzentry maraviroc 06-Aug-07 
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DRUGS THAT INHIBIT REVERSE TRANSCRIPTASE 
The enzyme reverse transcriptase (RT) is used by retroviruses to 
transcribe their single-stranded RNA genome into single-stranded DNA 
and to subsequently construct a complementary strand of DNA, 
providing a DNA double helix capable of integration into host cell 
chromosomes. Functional HIV1-RT is a heterodimer containing subunits 
of 66 kDa (p66) and 51 kDa (p51). The subunit p66 contains two 
domains, the N-terminal polymerase domain (440 residues) and the C-
terminal RNase H domain (120 residues). p51 is processed by 
proteolytic cleavage of p66 and corresponds to the polymerase domain 
of the p66 subunit. Portions of both p51 and the polymerase domain of 
p66 can be described as a "right hand" that contains three subdomains: 
fingers, palm, and thumb (Fig.1). The connection subdomain connects 
the hand of the polymerase domain and the RNase H domain in p66, 
which provides the ribonuclease activity of HIV-RT. Although p51 
contains a connection subdomain, it lacks an RNase domain. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Structure of HIV-1 RT complexed with dsDNA showing the relative location 
of the dNTP-binding pocket (in gold), the NNRTI binding site (in cyan), and the RNase 
H active site (in red). 
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Nucleoside analogue reverse transcriptase inhibitors 
 Due to its essential role in synthesizing the double-stranded 
proviral DNA from single-stranded HIV-1 RNA genome, the HIV-1 RT is 
a major target of current antiviral therapies directed against HIV-1. 
Nucleoside analogue reverse transcriptase inhibitors (NRTIs) represent 
an important class of compounds to treat infection with the human 
immunodeficiency virus type 1 (HIV-1). Six different NRTIs are today in 
clinical use. These compounds are intracellularly phosphorylated and 
compete with natural 2'-deoxyribonucleoside triphosphate (dNTP) pools 
for incorporation into the growing DNA chain.  
 
  
 
The nucleoside analogues such as zidovudine (azidothymidine, AZT) are 
comprised of a base (thymidine in the case of AZT) attached to a ribose 
sugar in which the normal 3’ hydroxyl has been replaced by an azido 
group.  
 
 
 
The presence of the 3’ OH is required for elongation of the growing DNA 
chain. Replacement of the OH at the 3’ position prevents bonds from 
being formed with this nucleoside. Incorporation of AZT into the 
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growing DNA chain in place of the normal nucleoside leads to a “chain 
termination” that stops polymerization of the growing DNA molecule.  
 The nucleotide analogues (eg, tenofovir) inhibitory mechanism of 
action is identical to that of the nucleoside analogues, with the main 
difference being structural in that tenofovir is an acyclic 
deoxyadenosine. Both nucleoside and nucleotide RT inhibitors must 
enter the cell and become phosphorylated in order to act as synthetic 
substrates for RT. Both classes of agents can prevent infection of 
susceptible cells but will have no effect on cells that already harbour 
HIV.  
Non-nucleoside analogues reverse transcriptase inhibitors 
 In addition to NRTIs, which are both competitive inhibitors and 
chain-terminators, the nonnucleoside reverse transcriptase inhibitors 
(NNRTIs) consist of structurally dissimilar hydrophobic compounds that 
directly bind reverse transcriptase at a hydrophobic pocket near the 
catalytic site (the binding site is formed by amino acids from codons 
100-110, 180-190 and 220-240 [8]), and alter the enzyme ability to 
change conformation. This increased enzyme rigidity prevents its 
normal polymerization. The side effects of the NNRTIs are generally less 
than those of the nucleoside analogues; however, the main 
disadvantage of these agents is the rapid development of resistance. As 
a result, the NNRTIs are never used for monotherapy of HIV infection.  
  
PROTEASE INHIBITOR DRUGS 
 Newly assembled HIV particles are not fully functional or infectious 
until they have undergone a final “maturation.” This maturation involves 
cleavage of viral protein precursors by HIV protease enzymes. These 
enzymes are encoded by HIV and offer a unique and attractive target 
for preventing HIV maturation.  
 HIV protease enzymes are symmetrical dimers with a central core 
that binds the peptides which require to be modified by the enzyme. 
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Three domains of the PR are frequently found in literature: the active 
site cavity, the dimerization domain, and the flaps (Fig. 3). 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3. Structure of HIV-1 protease 
 
 Protease inhibitors are designed to fit and bind at the catalytic site 
of the enzyme with high affinity and thereby block its activity.  
Inhibition of HIV protease enzymes still allows viral particles to be 
formed and released from host cells; however, the particles released 
are immature and not infectious.  
 
FUSION INHIBITORS. 
  Fusion of HIV with the host cell membrane is an essential step in 
the viral infectious activity. 
Entry of HIV-1 into target cells is a multistep process involving 
attachment (mediated by gp120 binding to CD4 lymphocytes), 
chemokine coreceptor binding, and association of 2 trimeric helical coils 
(HR-1 and HR-2) located in the ectodomain of gp41 into a 6-helix 
bundle that brings the virus and cell membranes into close 
approximation, allowing membrane fusion [9]. A number of drugs 
currently in development block HIV-1 infection by interfering with one 
DIMERIZATION 
DOMAIN 
FLAPS 
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or more of these steps. The recently approved fusion inhibitor 
enfuvirtide (known as T-20) blocks the association of HR-1 with HR-2 by 
binding to the trimeric HR-1 complex, thereby inhibiting fusion and 
blocking virus entry [10].   
 In August 2007 a new type of entry inhibitor known as maraviroc 
was licensed in the US. In Europe, it is available through an expanded 
access programme for people with few remaining treatment options, but 
still awaits full licensing. This new drug is known as a CCR5 inhibitor as 
it blocks the CCR5 co-receptor on human immune cells, preventing the 
HIV attachment to the cells surface. 
 
  
 While HAART regimens have decreased both the mortality and 
morbidity of HIV-infected patients, several factors contribute to therapy 
failure. The highly error-prone nature of HIV-1 RT combined with a 
robust rate of viral replication provides the virus with an ideal context 
for the emergence of resistant variants. In addition, the significant 
toxicity associated with the current anti-HIV drugs (showed in table 3) 
often leads to noncompliance, which may result in a treatment failure 
[11]. For these reasons, there is a high interest in the development of 
more potent anti-HIV inhibitors that are less likely able to lead to drug-
resistant variants and with a lower toxicity. 
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Table 3. Adverse effects of antiretroviral drugs. 
 
 
 
 
 
 
 
 
 
 
Drug class Example Adverse effects 
   Nucleoside,  
Nucleotide analogues 
Zidovudine 
Didanosine 
Lamivudine 
Abacavir 
Stavudine 
Emtricitabine 
Tenofovir 
Lactic acidosis 
Nausea 
 
   
Non-Nucleosides Nevirapine 
Efavirenz 
Rash  
Hepatotoxicity  
   
Protease inhibitors Ritonavir 
Saquinavir 
Amprenavir 
Indinavir 
Nelfinavir 
Atazanavir 
Tipranavir 
Fosamprenavir 
Hyperglycemia 
Nausea  
Diarrhea 
   
Fusion Inhibitors Enfuvirtide (T-20) Reaction at injection site 
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FAILURE DEFINITION 
 On the basis of clinical trials and cohort studies, approximately 20–
30% will experience treatment failure on their first regimen. Treatment 
failure can be defined in many ways [12]. These include: 
− virological failure (inability to achieve virological suppression or the 
occurrence of virological rebound),  
− immunological failure (progressive CD4 cell count decline), or  
− clinical failure (HIV disease progression).  
One or more of these may be present in each patient, and anyone of  
them may suggest the necessity to change the treatment. 
 It is critical to identify factors associated with treatment failure in 
order to adequately address them in the next regimen. Adherence 
problems are often present and, if they are, specific reasons for 
suboptimal adherence (dosing frequency, pill burden, drug–drug 
interactions, adverse event experiences, coexistent substance abuse, 
and so on) should be evaluated if possible to choose the next regimen.  
 At present, there are few recommended therapeutic options for the 
management of patients with highly resistant viral strains and severe 
therapeutic failure. The use of an antiretroviral regimen containing five 
to six active drugs, so called mega-HAART, has been reported to be at 
least partly effective in these patients [13].  
 
DRUG RESISTANCE. 
 Drug resistance to human immunodeficiency virus (HIV) is a major 
factor in the failure of antiretroviral therapy [14]. 
 Several factors related to the life cycle and replication of HIV are 
key contributors toward the rapid and widespread emergence of 
resistance.  
 First, the HIV reverse transcriptase (RT) enzyme is notoriously “low 
fidelity” (ie, the enzyme is somehow nonselective during the copying 
process) and is prone to errors when copying viral RNA into DNA. By 
some estimates, HIV RT makes one error in each HIV genome per 
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round of replication [15]. This translates into approximately 1 mutation 
for every 2000 nucleosides. Most of these errors are base substitutions, 
other mutations that can also occur are insertions or duplications. 
Second, HIV has an exceptionally high rate of replication; several billion 
new viral particles may be produced each day in the untreated patient.  
 Since the half-life of cells infected with HIV is generally 1-2 days, 
HIV must infect new cells at a very high rate to maintain the infection at 
a stable level. This high rate of replication coupled with the high rate of 
error for RT means that numerous HIV “variants” are rapidly formed 
and propagated. Patients who are infected with HIV can have multiple 
variants of the virus present in their system. These variants can have 
greatly different sensitivities to antiretroviral agents, a factor that can 
significantly complicate the selection of drugs and the course of 
therapy. Additional factors that may contribute to the development of 
HIV drug resistance, include poor patient compliance, subtherapeutic 
blood levels of antiretroviral agents, and inappropriate choice of 
antiretroviral agents. Patients should be told to take their HIV 
medications as prescribed and not to miss any doses. Pharmacokinetic 
factors that can affect blood levels of antiretroviral agents include poor 
oral absorption and alteration of drug metabolizing enzymes by other 
agents, as well as various drug-drug interactions.  
 While some HIV variants may exhibit intrinsic or “primary” 
resistance to antiretroviral agents, most drug resistance develops as a 
result of exposure to these agents. Antiretroviral resistance can still 
occur even during successful therapy of HIV infection [16]. Any 
mutations that confer a selective advantage to a particular viral variant 
will allow that particular viral variant to predominate. To some extend, 
the use of antiviral agents exerts a “selective pressure” leading to the  
development of more resistant viruses. The use of multiple drugs in 
combination may represent a strategy able to reduce the ability of 
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 The major implications of drug resistance include a change in viral 
fitness, possible changes in viral tropism, an interaction in the 
susceptibility to other drugs.  
In particular, cross-resistance (defined as resistance to drugs to which a 
virus has never been exposed) within a given class of antiretroviral 
agents has been found to affect all classes of drug currently available 
[17]. Compared with single-drug resistance, this cross-resistance may 
result in class-wide resistance (CWR), which could substantially reduce 
the clinical utility of antiretroviral drugs of the same class and reduce 
future treatment options [18]. 
Resistances may be classified as follow: 
 Genotypic resistance: the presence of genotypic changes that 
reduce the sensitivity to one or more drugs; 
 Phenotypic resistance: the capability of a virus to grow in the 
presence of a drug concentration in witch a wild type virus 
replication is blocked. 
 According to the time of acquisition of drug resistance, we can 
differentiate a primary resistance, which is drug-resistance mutations 
detected in antiretroviral naive-patients, and a secondary resistance, 
which is drug-resistance mutations detected in antiretroviral 
experienced-patients. 
 Drug pressure drives selective forces for genetic changes in the 
viral genome. Mutations arising under antiretroviral therapy allow virus 
to escape from the inhibitory effect of the drug on virus replication. Two 
major classes of drug resistance mutations have been identified as: 
 
 
Primary mutations: 
 Selected early in the process of resistance to one drug. However, 
they may be selected or favoured after the appearance of some 
secondary mutations. These mutations have an high degree of 
specificity for one drug witch significantly compromises the 
susceptibility of the virus for that drug; 
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Secondary mutations: 
 Tend to accumulate in viral genomes already containing one or 
more primary mutations, they may have little or no effect on the level 
of resistance, but they may increase viral replication by increasing viral 
fitness. 
 
Genetic barrier is a terminology referred to the number of mutations 
required of reducing or loosing the drug antiretroviral activity. Genetic 
barrier may be classified as  
− low: loss of antiviral activity by the appearance of a single 
mutation. It is a relatively easy hurdle for the virus to overcome. 
− High: loss of antiviral activity after the appearance of multiple 
mutations 
 
However, it is not necessary a high level of resistance for virological or 
immunological treatment failure. 
 
 
RESISTANCE TO ANTIRETROVIRAL DRUGS 
1. NRTI. 
 Resistance to NRTIs occurs through 2 mechanisms: the first is 
mutation of the residues that results in reduced incorporation of the 
NRTI into the growing DNA chain. It is now well accepted that primer 
unblocking (i.e. nucleotide excision) is the mechanism of zidovudine 
resistance. Primer unblocking is the mechanism by which 
pyrophosphate or ATP can remove the terminal nucleotide from a 
growing DNA chain [19]. This reaction (in essence the reversal of DNA 
synthesis) can result in removal of zidovudine, thereby relieving the 
block to reverse transcription.  
 The second mechanism of NRTI resistance is associated with 
enhanced removal of drug from its site of attachment at the end of the 
DNA chain. These RT mutations allow ATP or pyrophosphate (both of 
which are in high concentration within the cell) to bind at the active site 
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adjacent to the bound nucleoside analogues. The high energy ATP or 
pyrophosphate can then attack the bond that binds the drug to DNA, 
thereby liberating the drug and terminating its effect. 
 Multi-NRTI resistance mutations, also known as nucleoside 
analogue-associated mutations (NAMs), are associated with resistance 
to numerous NRTIs. TAMs (thymidine analog mutations) are a subset of 
NAMs that are selected by the thymidine analogues zidovudine and 
stavudine and are associated with cross-resistance to all NRTIs 
currently approved by the US FDA. 
 The M41L, D67N, K70R, L210W, T215Y/F, and K219Q/E are known 
as TAMs. These resistance mutations increase the rate of nucleotide 
excision by reverse transcriptase. In contrast, others reverse 
transcriptase mutations (e.g. M184V, Y181C) slow  the rate of excision.  
 Others important resistance mutations implicated in the cross-
resistance are the complex Q151M (A62V, V75I, F77L, F116Y, Q151M) 
(20,21) and the 69 insertion complex, that consists of a substitution at 
codon 69 (typically T69S) and an insertion of 2 or more amino acids (S-
S, SA, S-G, or others). The 69 insertion complex is associated with 
resistance to all NRTIs currently approved by the US FDA when present 
with 1 or more thymidine analogue-associated mutations (TAMs) at 
codons 41, 210, or 215. Other amino acid changes at codon 69 without 
the insertion may also be associated with broad NRTI resistance.  
 Several studies analysed V118I substitution, that seems decrease 
the susceptibility to multiple nucleoside analogues by a reduction in 
rates of their incorporation [22]. Several clinical data revealed that 
mutations E44D and V118I, when present in a background of classical 
AZT-mutations (M41L, D67N, L210W, and T215Y), confer dual 
resistance to AZT and 3TC [23]. V118I lies in close proximity to 
residues Y115 and F116, which interact with the incoming nucleotide. 
Changes at these positions were shown to have profound effects on the 
ability of RT to discriminate between correct and incorrect nucleotides. 
The prevalence of the E44D/A and/or V118I mutation increases with the 
 17 
number of antiretroviral treatments, and this suggests that the 
mutation might be involved in a more broad-spectrum nucleoside 
resistance. 
  
2.NNRTI 
 Resistance to this class of agents occurs mainly through mutation 
of hydrophobic RT residues within the binding pocket for the NNRTIs. 
Since all of the NNRTIs bind to essentially the same region of RT, 
mutations in this area will affect binding of all of the agents in this 
class. This may in part explain the high rates of HIV cross-resistance 
within this class of agents [24]. 
 The most common mutations in viruses isolated from patients 
treated with NNRTI are Y181C and K103N. Mutations of residue 190 
(mostly G190A/S) represent approximately 15% of NNRTI-resistant 
variants and confer variable levels of drug resistance and fitness [25]. 
Variants carrying the G190E mutation are linked to reduced 
susceptibility to NNRTI, but show impaired replication with significantly 
reduced polymerase, RNase H and protease activities.  
 Numerous NRTI mutations, such as the TAMs M41L, L210W, and 
T215Y mutations, may lead to viral hypersusceptibility to NNRTIs in 
NRTI-treated individuals. The presence of these mutations may improve 
subsequent virologic response to NNRTI-containing regimens in NNRTI 
treatment-naive individuals [26],[27].  
 
Several studies demonstrate that different combinations of V118I, 
H208Y, and T215Y produce NNRTI hypersusceptibility, while single 
mutations V118I, H208Y, and T215Y don’t show this hypersusceptibility 
[28] [29]. 
 The exact mechanism responsible for the action of these 
polymorphisms is still unknown. Several authors propose a mechanism 
of stabilization in the three-dimensional structure of the enzyme that 
could be explained by the structural vicinity of the mutations at 
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positions 208, 211, and 214 to the ZDV-associated mutations L210W 
and T215Y/F.. 
Figure 2 shows the DNA polymerization active site of HIV-1 RT with 
commonly observed drug-resistance mutation sites for NRTI and for 
NNRTI.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. A view of the DNA polymerization active site of HIV-1 RT with commonly 
observed drug-resistance mutation sites for nucleoside inhibitors (in gold) and for 
non-nucleoside inhibitors (in cyan).  
 
3. PI 
 Resistance to protease inhibitors occurs primarily as a result of 
amino acid mutations that arise within or proximal to the catalytic 
binding site to the drug. Replacement of key amino acids within the 
protease enzyme can significantly alter the affinity of the enzyme for 
binding protease inhibitors. In addition, the geometry of the catalytic 
site is altered and enlarged by these mutations. Since the protease 
inhibitors bind the catalytic sites with significantly higher affinity than 
the natural substrates, mutations in this region will have a greater 
effect on drug binding than on the endogenous peptides. 
 19 
 Resistance mutations in the protease gene are classified as “major” 
or “minor” (table 4) 
 
Table 4. HIV protease inhibitor resistance mutations 
Protease inhibitor resistance mutations according to the IAS-US A panel for ARV resistance 
Protease Inhibitor 
drug 
Cross-resistance mutations Unique mutations 
Number of 
resistance 
mutations 
 Major Minor Major Minor  
Saquinavir/r L90M, 
G48V 
L10IRV,24I,4VL,62V,71VT,73S, 
77I,82AFTS,84V 
  2 or more 
Indinavir/r 46IL,82AF
T,84V 
L10IRV,20MR,24I,32I,36I,54V, 
71VT,73SA,77I,90M 
  3 or more 
Nelfinavir L90M 
L10FIRV,L24I,M36I,M46IL, 
A71VT,G73S,V77I,V82AFTS, 
I84V,N88DS 
D30N 
 
 2 or more 
Fosamprenavir/r I50V 
L10FIRV,V32I,M46IL,I47V, 
I54LVM,G73S,V82AFST,L90M 
  3 or more 
Lopinavir/r 
V32I,I47V
A,V82AFT
S 
L10FIRV,K20MR,L24I,L33F, 
M46IL,I50V,F53L,I54VLAMTS, 
A71VT,G73S,I84V,I90M 
 
L63P 
 
6 or more 
Atazanavir/r I84V,N88
S 
L10IFVC,K20RMITV,L24I,V32I, 
L33IFV,M36ILV,M46IL,G48V, 
F53LY,I54,LVMTA,I62V,A71VITL, 
G73CSTA,V82ATFI,L90M 
I50L 
 
G16E,E34Q, 
D60E, 
I64LMV,I93LM 
 
3 or more 
Tipranavir/r L33F,V82L
T,I84V 
L10V,K20MR,E35G,M36I,K43T, 
M46L,I47V,I54AMV,L90M 
 
I13V,Q58E, 
H69K,T74P, 
N83D 
7 or more 
Darunavir/r 
I50V,I54M
L, 
I84V 
V11I,V32I,L33F,I47V,G73S 
L76V 
 
V11I,L89V 3 or more 
 
Major mutations in the protease gene are defined either as those 
selected first in the presence of the drug, or those shown at the 
biochemical or virological level leading to an alteration in drug binding 
or an inhibition of viral activity or viral replication.  
 Major mutations have an effect on drug susceptibility phenotype. In 
general, these mutations tend to be the primary contact residues for 
drug binding. Minor mutations generally emerge later than major 
mutations, and by themselves do not have a significant effect on 
phenotype. In some cases, they may improve replicative fitness of the 
virus containing major mutations [30]. 
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 Certain PI resistance mutations cause limited or no cross-resistance 
to other agents. Nelfinavir can select for D30N; atazanavir for I50L; and 
fosamprenavir for I50V.  Importantly, 150V can reduce susceptibility to 
lopinavir if other PI resistance mutations are present. When these 
individual mutations are selected, the response to ritonavir-boosted PIs 
is usually preserved.  
UPAMS are the universal protease-associated mutations (L33I/V/F; 
V82A/F/LT; I84V and L90M) that confer broadly cross resistance among 
all available protease inhibitors. 
 
4. FUSION INHIBITORS 
 Although just introduced to clinical practice, varying susceptibility 
of different HIV strains to enfuvirtide has already been documented 
[31]. 
Mutations in HR-1 that reduce enfuvirtide susceptibility are selected by 
in vitro passage of HIV-1 in the presence of the drug and have been 
identified in isolates obtained from patients receiving enfuvirtide in 
clinical trials [32]. In particular, amino acid substitutions at gp41 
codons 36–45, which are part of the binding site for enfuvirtide, are 
found in virus samples recovered from patients experiencing protocol-
defined treatment failure of enfuvirtide and are associated with an 
average 20-fold increase from the baseline IC50 of enfuvirtide [33]. The 
500-fold range of enfuvirtide susceptibility among pretreatment isolates 
with wild-type sequences in HR-1 suggests that sequence variation in 
other regions of the HIV-1 envelope modulate susceptibility to this drug. 
 
Genotypic diversity among HIV-1 subtypes may lead to different 
pathways to drug resistance.   
 In order to provide effective pharmaceutical care to their HIV 
patients, it is essential that the practitioners understand the 
mechanisms of HIV drug resistance as well as the various factors that 
can contribute to its emergence. 
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 Resistance testing is critical to the construction of an active 
regimen in treatment-experienced patients [34] 
 The test must be done while the patient is on therapy in order to 
identify reliable resistance mutations. It is also important to be aware of 
prior resistance mutations that may have developed but whose 
presence may not be evident on the most recent assay. In most 
instances drug resistance that has been acquired from prior treatment 
failure cannot be reliably detected from a resistance test if the patient 
has been off therapy for a few months or if the current regimen does 
not continue to force the virus to sustain the mutations in question 
[35]. 
 Resistance results must be analyzed aware of the current and 
previous treatment regimens of the patient, in order to properly 
modified the patient therapy. 
 The interpretation of HIV genotypic assays in clinical settings is 
very difficult because of the large numbers of drug resistance mutations 
and because these mutations interact one with another one and emerge 
in complex patterns. 
 
 The type of resistance test (genotype or phenotype) that is most 
helpful in making good treatment decisions likely differs for specific 
patient situations. Nonetheless, the most difficult it is likely to be to 
interpret the resistance genotype. The interactions among various 
mutations may be unpredictable as they relate to each drug, making 
the interpretation of genotypic results a big challenge. In this setting it 
is almost always simpler to interpret phenotypic tests. The genotype 
may complement the phenotype, and many experienced clinicians 
prefer to have both genotype and phenotype resistance test results 
available to guide drug selection in these often very difficult patients. 
The main goal of resistance test interpretation is to identify at least two 
active drugs that can be prescribed to suppress viral replication [36]. 
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 The greatest availability of genotype tests and its lower cost have 
allowed its wider introduction compared to the phenotype assays.  
The question that remains now is how best to help a physician with 
interpreting genotypic information. It seems that 3 different approaches 
are helpful: 
1. the clinician consults with the expert on a case-by-case basis. 
However this is not always feasible because many clinicians may not 
have access to an expert advisory. 
2. “Rule-based” system. These rules are described in a table or 
generated from a computer as part of a genotype report, such the 
TrueGene™ HIV report that is supplied with the commercially available 
Visible Genetics genotype test. These rules are set by a panel of experts 
based on current knowledge, and require continual updating. 
3. “database-driven predicted phenotype”. In this form of 
interpretation, the patient’s genotype is matched with other similar 
genotypes found in a genotypic/phenotypic relational database. 
 
 
There are four sources of data that form the basis for drug resistance 
knowledge:  
1. Genotypic-phenotypic correlations on laboratory isolates (often 
confirmed by site-directed mutagenesis studies);  
2. Genotypic-phenotypic correlations on clinical HIV-1 isolates;  
3. Correlations between HIV-1 genotype and the treatment history 
of patients from whom sequenced virus isolates are obtained;  
4. Correlations between HIV-1 genotype and the virologic response 
to a new treatment regimen. 
 
 
RESISTANCE ASSAYS 
 The development of genotypic and phenotypic tests has help to 
guide the therapeutic management in HIV-infected patients. There have 
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been a number of both prospective and retrospective studies that have 
demonstrated the clinical benefit of resistance testing. Currently, it 
exists several techniques that allow us to analyze the HIV genotype and 
phenotype. 
Available testing includes HIV-1 genotype, phenotype and virtual 
phenotype determined from plasma samples using automated assays. 
 Genotypic testing/genotyping: test conducted to determine the 
nucleotide sequence of the virus genome. The results are provided as a 
list of changes in any amino acid or mutation that is different from the 
wild type reference strain. Such mutations are expressed by the 
position they have in a certain gene (codon), preceded by the letter 
corresponding to the amino acid seen in the wild type virus, and 
followed by the mutated amino acid. Example: M184V would correspond 
to the substitution of the amino acid Methyonine by Valine in codon 184 
of the retrotranscriptase gene. 
Phenotypic testing/phenotyping: test conducted to determine the 
susceptibility of a virus to drugs in a virus culture assay. The results 
may be expressed as: 
IC50, IC90, IC95: Concentration (in µg/ml or µM) of the drug needed to 
inhibit the viruses growth in vitro by 50%, 90% or 95%, respectively. 
 
Fold changes = 
  
 
Virtual Phenotype 
 It is the predicted HIV drug resistance from the genotype. When a 
genotype for patient sample is generated, the genetic code for the RT-
PR regions is added into a software system. This system identifies all 
the mutations that can affect resistance to each drug and then 
interrogates the database for genotypes from previous samples that 
match these patterns of mutations. When all the matches are identified, 
the software retrieves the phenotypes for these samples and, for each 
IC50 from the patient isolate  
 
IC50 from a sensitive laboratory strain 
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drug, averages the data for the matches. This produce a Virtual 
Phenotype, with a fold change in IC50 for each drug that is typically 
based on data from hundred of real phenotypes with the same pattern 
of mutations [37].  
 
COMPARISON BETWEEN THE RESISTANCE TESTS 
 Genotypic assays analyze the HIV genome in order to detect 
specific mutations responsible for drug resistance. Interpretation of 
genotypic assay results is done by matching the results from the 
individual virus against lists of frequently updated HIV mutations that 
are known to confer drug resistance. These genotypic assays are 
relatively inexpensive and may now be performed rapidly on site with 
commercially available assay kits. However, genotypic testing can only 
identify documented HIV mutations and may not detect new mutations 
that arise in a particular HIV variant. In addition, since different 
mutations confer different degrees of drug resistance, it is often difficult 
to predict the actual degree of clinical drug resistance in a virus with 
multiple mutations. 
 In contrast, phenotypic resistance assays examine the actual drug 
susceptibility of a particular HIV variant. HIV genes for reverse 
transcriptase and protease enzymes are amplified and inserted into a 
recombinant virus which is then exposed to various anti-HIV drugs. 
Phenotypic testing provides information on the sensitivity of a particular 
HIV variant in comparison to a control isolate with full drug sensitivity. 
One practical difficulty associated with phenotypic testing is translating 
observed decreases in viral drug sensitivity in the assay into actual 
decreases in clinical sensitivity. What degree of phenotypic resistance 
needs to be present for each drug in order to see actual decreases in 
clinical effectiveness for that drug? It is only through large-scale clinical 
trials that an actual correlation might be made between changes in 
phenotypic sensitivity and actual drug resistance. So far these 
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clinical/phenotypic correlations have only been done for a few anti-HIV 
drugs [38].  
 The nature of phenotypic testing makes assays more technically 
difficult and expensive, thus such testing is only carried out at dedicated 
commercial facilities. 
The virtual phenotype is faster and less expensive than a phenotypic 
test. 
 
The ability to detect HIV-1 non-B subtypes is still not well known on 
both genotypic and phenotypic assays. However, some studies have 
reported amplification and successful resistance analysis for all group M 
(A-H) subtypes [39,40].  
 
RELEVANCE OF RESISTANCE TESTING IN CLINICAL CARE 
 In addition to resistance testing also other factors should be 
considered in order to choose the best pharmacological therapy for a 
rescue intervention in patients with virological failure. Between these, 
we mention: 
− Drug treatment history 
− Plasma viral load 
− CD4+ lymphocytes 
− Medication tolerance 
− Adherence 
− Concomitant medications 
− Blood and cellular drug levels  
 
 Many practicing physicians and clinical investigators might not be 
aware about the fact that the most conventional knowledge about drug 
resistance derives from studies performed solely during the pre-clinical 
and early clinical development of a new drug. Information arising after a 
drug has been approved by the FDA and has been incorporated as a 
clinical tool often not included on many of the "gene charts" that many 
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physicians and reference labs rely on for interpreting genetic sequence 
data. The final resistance report is often limited to the amino acid 
positions that are known to be involved in drug resistance [41]. 
Thousands of patients may have been treated inappropriately because 
sequence interpretations based on such oversimplified charts which in 
consequence  might can be inaccurate. Additionally, complacent reliance 
on simple yet inaccurate data has masked the need for the additional 
research necessary to interpret genotypic tests in a clinically meaningful 
manner [42]. 
  
 In this study we described the genotypic state of 12 HIV-1 positives 
patients with an history of multiple failure. Our data are based on two 
consecutive genotypic resistance tests and the therapy choices made 
for these patients. The aim was to evaluate the usefulness of analyzing 
other nucleotide polymorphism (not considered in the resistance report 
because not associated with drug resistance, or because mutations in 
resistance sites, but of a yet unclear significance). 
The analysis were performed in two steps:  
1) Complete analysis of the two consecutives tests; 
2) New interpretation of the same tests following guide lines G12 
updated to 2006. 
In the first step we evaluate if the development of new resistance 
mutations in the second test was already observable in the research 
report of the previous test between the mutations in sites already 
known to be associated to a resistance . 
In a second time we made a new interpretation of the first sequences 
and we observed the differences in the mutations, witch lead to a 
difference of the two reports. 
 
We have then analysed the therapeutic choices made for these patients 
on the basis of the resistance test in order to determine the weight of 
these additional informations in the best choice of the best therapy.   
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METHODS 
 
Samples preparation 
 EDTA plasma samples were collected and stored in a freezer at -
80°C until use. 
HIV-1 RNA quantitation  
 The viral load determination, parameter evaluated to monitor HIV-
positives patients, is necessary to decide the resistance test 
performability. The test can be performed with viral loads>1000 
copies/ml, even if a more low viral load (250-500 copies/ml) is 
sufficient for certain patients. 
 HIV-1 RNA copy number was assessed using until 2006 the HIV-1 
Amplicor™ Monitor (Roche) and since 2006 the Versant® HIV-1 RNA 
3.0 assay (b-DNA) (Bayer).  
The bDNA (branched DNA) technology, in contrast to PCR, amplifies the 
non-isotopic signal of a direct hybridization to the target sequence and 
the signal amplification is linear. The assay is a sandwich nucleic acid 
hybridization procedure for the direct quantification of HIV-1 RNA in 
human plasma.  
Briefly, the enclotted (EDTA) whole blood samples are centrifuged at 
2000 rpm for 10 minutes and plasma  is stored at -20°C until use. HIV-
1 is first concentrated from plasma by centrifugation (14000 g for 70’). 
After HIV-1 genomic RNA is released from the virions, the RNA is 
captured to a microwell by a set of specific, synthetic oligonucleotide 
capture probes. A set of target probes hybridize both the viral RNA and 
the pre-amplifier probes. The capture probes, comprised of 17 
individual capture extenders, and the target probes, comprised of 81 
individual target extenders, bind to different regions of the pol gene of 
the viral RNA. The amplifier probe hybridizes to the pre-amplifier 
forming a branched (bDNA) complex. 
 Multiple copies of an alkaline phosphatase (AP) labelled probe are 
then hybridized to this immobilized complex. Detection is achieved by 
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incubating the complex with a chemiluminescent substrate. Light 
emission is directly related to the amount of HIV-1 RNA present in each 
sample, and results are recorded as relative light units (RLUs) by the 
analyzer. A standard curve is defined by light emission from standards 
containing known concentrations of HIV-18E5/LAV virus. Concentrations 
of HIV-1 RNA in specimens are determined from this standard curve. 
The lower detection limit of RNA quantification for this assay is 50 
copies/ml. 
 
HIV-1 resistance evaluation from RNA. 
 For HIV-1 sequencing, plasma RNA was extracted using the High 
Pure Viral Nucleic Acid Kit (Roche Applied Science).  
 Virus lysis is accomplished by incubation of the sample (plasma) in 
a special lysis/binding buffer in the presence of proteinase K. 
Subsequently, nucleic acids bind specifically to the surface of glass 
fibers in the presence of a chaotropic salt. The binding reaction occurs 
within seconds due to the disruption of the organized structure of water 
molecules and the interaction of nucleic acids with the glass fibers 
surface. Since the binding process is specific for nucleic acids, the 
bound nucleic acids are purified from salts, proteins and other 
impurities by a washing step and are eluted in low salt buffer or water.  
 Reverse transcriptase polymerase chain reaction (RT-PCR) and 
direct DNA sequencing of protease and reverse transcriptase genes 
were performed using the TruGene® HIV-1 Genotyping Kit and the 
OpenGene™ DNA Sequencing System (Visible Genetics-Bayer 
Diagnostics, Toronto, Canada) according to the manufacturer's 
instructions.  
 This test allows to detecting HIV genomic mutations (in the 
protease and part of the reverse transcriptase regions of HIV), that 
confer resistance to specific types of antiretroviral drugs. These two 
regions code for the main targets of antiretroviral treatment. 
Development of viral resistance to these drugs is associated with 
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mutations within these coding regions. The mutations are identified by 
sequencing an RT-PCR product corresponding to these regions, and 
comparing the sequence to a wild type virus reference standard.  
 
The TRUGENE HIV-1 Genotyping Assay consists of several processes: 
1. Reverse transcription of target RNA to generate cDNA using RT-
PCR amplification of target cDNA using HIV-1 specific primers; 
2. CLIP sequencing of the PCR amplicons using HIV-1 specific 
primers; 
3. Separation of the CLIP sequencing reactions by electophoresis on 
a polyacrylamide gel, and detection by laser-induced 
fluorescence; 
4. Analysis of the forward and reverse CLIP sequences using the 
OpenGene DNA System Software. The end result is a Trugene 
HIV-1 Resistance Report for each sample. 
 The HIV-1 pol genes for the protease and reverse transcriptase 
regions are 297 and 1680 nucleotides in length (99 and 560 amino 
acids) respectively and are located at positions 1835-4678 (including 
the RNase H region) in the pol region of the HIV-1LAV-1 genome  
(GenBank number K02013). Due to the highly polymorphic nature of 
HIV-1, a mixture of several primers targeted at the most common viral 
variants are used in this kit. 
 The resistance report include relevant mutation, associated to 
resistance toward a particular drug, on the basis of four possible 
“evidence rules”: 
I – rule based on two or more independent studies of virological 
response and other in vitro data.  
II – rule based on in vitro data (phenotype’s data and/or in vitro 
demonstration of mutation) and preliminary data of virological 
response; 
III – rule based on in vitro data.  
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IV – rule based on Consensus Panel extrapolation. Do not exist in vitro 
or in vivo data. 
 Apart from the resistance report, the software elaborate an other 
research report, with all polymorphism not involved in the drug 
resistance.  
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Results. 
Description of the study population 
 Of the 450 patient HIV-infected attending our Immunology Centre 
about a 10% are in an advanced stage of infection and in an advanced 
line of treatment. The analysed sequences derive from 12 HIV-1 
positives patients for witch a genotypic resistance test was performed 
for reason of virological failure. We considered two consecutive 
resistance tests for each patient, performed between 2001 and 2004 
and between 2003 and 2007 respectively, and analysed by several 
“libraries” (guide-line rules), from “g4” to “g11”.  
All patients was in a relatively advanced stage of infection. According to 
the Center for Disease Control and Prevention classification, 6 (50%) 
patients were in  stage B3, 3 in stage C3, 2 in stage B2 and 1 in stage 
C1. 
 All patients begun therapy between 1992 and 1996 and received 
several previous treatment (more of 6 therapy cycles with all three 
class NRTI, NNRTI, PI), with multiple treatment failure. 
Median viral load was of 16700 HIV-1 RNA copies/ml (range 3570 to 
380000 HIV-1 RNA copies/ml) at the time of first test and 6090 HIV-1 
RNA copies/ml (range 1800 to 81367 HIV-1 RNA copies/ml) at the time 
of second test. The time mean elapsed between the two tests was 
21.17 ± 2.39 months. 
 
 Viral load, therapy regimen at the time of the two genotyping 
analysis (that we labelled time 1 and time 2), the following therapy 
switch, the response of the patients (intending as positive response a 
viral load <50 copies/ml within six months) and the months elapsed 
between the two resistance tests are showed in table 7. During this 
period not necessarily was maintained the same therapeutic regimen, 
but for certain patients were made empiric modification on the basis of 
previous therapeutic history and previous resistance test.  
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Tab 7. Therapy and switch therapy following the resistance test interpretation  
Time 1 
M. 
diff 
Time 2 
P 
VL 
(cps/ml) 
Therapy Switch Resp  
VL 
(cps/ml) 
Therapy Switch Resp 
1 26100 
d4T,EFV, 
LPV/r 
3TC,ddI,LPV/r N 17,59 4420 
FTC, 3TC, 
ddI, LPV/r 
3TC,ddI,TDF, 
LPV/r 
Y 
2 6950 
ddI, d4T, 
ABC,LPV/r 
ddI,TDF,EFV N 9,27 3170 
3TC, d4T, 
LPV/r 
NO SWITCH N 
3 39100 
AZT, ddI, 
LPV/r 
3TC,EFV,LPV/r Y 23,11 1800 
3TC, TDF, 
LPV/r 
NO SWITCH N 
4 6070 
ddI, d4T, 
EFV 
ddI,d4T,SQV, 
RTV 
N 35,90 5110 
FTC, d4T, 
LPV/r 
NO SWITCH Y 
5 8460 
ddI, ABC, 
LPV/r 
NO SWITCH N 27,55 29400 
TDF,ABC, 
LPV/r 
NO SWITCH N 
6 16300 
d4T,ABC, 
LPV/R 
3TC,d4T,EFV Y 15,32 5790 
TDF, d4T, 
LPV/r 
3TC,TDF, 
LPV/r 
Y 
7 7620 
3TC, ddI, 
TDF, d4T, 
LPV/R 
NO SWITCH N 18,77 6390 
3TC, AZT, 
LPV/r 
3TC,AZT, 
LPV/r 
N 
8 380000 
ABC, AZT, 
3TC, ddI, 
SQV 
3TC,d4T,NFV N 12,13 67500 
TDF, FTC, 
ddI, TPV, 
RTV 
ddI,TDF, 
LPV/r 
N 
9 29400 
3TC,TDF, 
d4T,APV, 
RTV 
NO SWITCH N 25,41 45500 
TDF,EFV, 
RTV, ATV 
NO SWITCH N 
10 >100000 
ddI, d4T, 
APV,RTV 
3TC,TDF,EFV N 25,74 81367 
FTC, TPV, 
RTV 
AZT,TDF,FTC N 
11 3570 
3TC, AZT, 
ATV 
AZT,TDF,EFV Y 12,13 5232 
AZT, TDF, 
EFV 
TDF,FTC, 
LPV/r 
Y 
12 17100 
ddI, d4T, 
LPV/r 
SUSPENSION 
 6 MONTHS 
N 31,07 13900 
3TC, TDF, 
d4T, EFV, 
APV, RTV 
3TC,TDF, 
LPV/r 
N 
 
 There wasn’t a therapy switch for 3 patients (25%) at time 1, and 
for 5 patients (41.7%) at time 2, two of which being the same. 
There was a positive response following the resistance test for 3 patient 
at time 1, and for 4 patients at time 2. 
The more used drugs at time 1 were didanosine and stavudine between 
NRTIs (68%), and lopinavir/ritonavir between PIs (58%), while at time 
2 were tenofovir (58%) and stavudine (42%) between NRTIs, and 
lopinavir/ritonavir (42%) between PIs (figure 1). 
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The mean viral load of the overall at time 2 is resulted  lower than at 
time 1, but this difference was not statistically significant (figure 2) 
 
 
 
Figure 2. Viral load  
 
 No significant differences were found in viral load between 
responders and non responders patients.  
In tables  8 (A/B), 9 (A/B) e 10 (A/B) we listed all the mutations witch 
appear in the resistance report and in the research report too. 
In particular, in table 8 (A/B) we listed the mutations present in the 
resistance report. 
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Table 8.A.  Resistance mutations. Time 1. 
P NRTI mutations 
NNRTI 
mutations  
PI  mutations 
1 M41L, Q161Q/L, T215Y K103N, Y188L 
L10I, K20R, M36I, M46L, G48V, I54V, A71V, V82S, 
L90M 
2 
E44D, A62V, K65R, L74V,  
V75I, M184V, L210W, 
T215N/T/S/Y 
V118I 
L10I/L, K20K/I/M, M36I/M, M46I/M, F53L/F, I54I/V, 
L63P, A71A/V, G73S/G, V82A/V, L90M/L 
3 M41L, D67N, L210W, T215Y / M46I, I54L, L63P, I84V, L90M 
4 M41L, L210W 
K101E, Y181C, 
G190A 
L10F, K20M, L24I, M36I, M46I, I54V, L63P, A71V, 
V82A 
5 M41L, D67N, L210W, T215Y V118I 
L10F, K20R, L24I, M36I, M46I, L63P, A71V, G73S, 
V82A, I84V 
6 M41L, D67N, L210W, T215Y / 
M36I/M, M46I, I47I/V, I54V, L63P, A71V, G73S, 
I84V, L90M 
7 
M41L, D67N, M184V, 
L210W, T215Y 
V118I 
L10I, L33F, M46I, F53L, L63P, A71V, G73S, V82A, 
L90M 
8 / / L63P 
9 
M41L, M184V, L210W, 
T215Y 
V118I K20R, M36I, I54V, L63P, A71V, I84V, L90M 
10 F116Y, Q151M, T215D / L10I, M36I, M46I, I54V, L63P, A71T, L90M 
11 
D67N, K70R, M184V, 
T215F, K219Q 
/ M36I, M46L, I50L, L63P, A71V, G73S, L90M 
12 
M41L, E44D, D67N, M184V, 
L210W, T215Y 
V118I L10I, M46I, I54I/L, L63P, I84V 
 
Table 8.B. Resistance mutations. Time 2. 
P NRTI mutations NNRTI mutations  PI  mutations 
1 M41L, M184V, T215Y K103N, Y188L 
L10I, K20R, M36I, M46L, G48V, I54V, 
A71V, V82S, L90M 
2 
M41L, E44D, A62V, L74V,  
L210W, T215Y 
K101K/E,V118I,Y181C,G190S 
L10I, K20I, L33I, M36I, M46I, I54V, 
L63P, A71V, G73S, V82A, L90M 
3 
M41L, D67N, M184V, 
L210W, T215Y 
K103N 
L10F, M36I, M46I, I54L, L63P, A71V, 
G73T/S, I84V, L90M 
4 M41L, L210W, T215Y K101E, V118I, Y181C, G190A 
L10I, K20M, L24I, M36V, M46I, F53L/F, 
I54V, L63P, A71V, V82A 
5 M41L, D67N, L210W, T215Y V118I 
L10F, I13V, K20R, L24I, L33I, E34Q, 
M36I, M46I, L63P, A71V, G73T, V82A, 
N83D, I84V 
6 
M41L, D67N/D, M184V, 
L210W, T215Y/C 
K103N, V108I 
L10F, M36I, M46I, L63P, A71V, G73S, 
I84V, L90M 
7 
M41L, D67N, M184V, 
L210W, T215Y 
V118I 
L10I, L33F, M46I, F53L, I54V, L63P, 
A71V, G73S, V82A, L90M 
8 M184V, T215Y / L63P, L90M/L 
9 M41L, L210W, T215Y L100I, K103N, V118I 
K20R, M36I, M46L, I54V, L63P, A71I, 
I84V, L90M 
10 
Y115F, F116Y, Q151M, 
M184V, T215D 
K103S, Y188H, H208Y 
L10I, I13V, K20I, M36I, M46I, I54V, 
L63P, A71T, G73T, I84V, L90M 
11 D67N, K70R, T215F, K219Q K103N, Y181C, P225H/P 
M36I, M46L, I50L, L63P, A71V, G73S, 
L90M 
12 
M41L, E44D, D67N, V75M, 
M184V, L210W, T215Y, 
K219Q 
V118I, G190S L10I, M46I, L63P, I84V 
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 At time 1 all patients but 1 (pz. 8) show three or more mutations at 
the transcriptase gene and five or more mutations at the protease gene. 
The presence of thymidine-associated mutations (TAMs) were more 
common.  
 Five patients of 12 (patients 3, 6, 8, 10, 11, about 42%) don’t 
show mutations toward NNRTIs. Between the 7 patients that show 
these NNRTIs mutations, the prevalent mutation (in 5 patients) was the 
V118I.  
. 
 At time 2 appear one or more mutations toward the NNRTIs as well 
in those patients with no mutations at time 1, but in no one of those 
appears the V118I mutation. 
 It’s likely to be a lack of therapy adherence at time 1 for patient 8, 
highlighted by any mutation in RT in spite of the therapeutic regimen. 
For what this patient concern we can consider the resistance test an 
helpful tool in the determination of the reason of the failure, and in 
particular to detect it was due to the virus undisturbed replication rather 
than on a virus resistance.   
 In table 9 (A/B) we listed silent mutations or other mutations in 
resistance sites, and in table 10 (A/B) we listed the mutations in codons 
not known to be associated to a resistance in that time. No significant 
differences were found between responders and non responders 
patients considering the number of these polymorphisms.  
Only in two patients of 12 (patients 2 and 4) some of mutations in sites 
of resistance, and only for the transcriptase gene, evolved in resistance 
mutation included in the report at time 2, and these were Y181Y, 
G190G and M41I/M for patient 2 and T215T for patient 4. 
 
 With new interpretation we observed in the report some adjunctive 
mutations (table 11 A/B). 
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Table 9.A.  Resistance sites . Time 1 
 Silent mutations Others mutations 
P RT PR RT PR 
1 L100L / V179I L63A 
2 
K103K,V106V,Q151Q,Y181Y, 
G190G,F227F 
/ 
M41I/M,D67D/G 
 
L24L/F 
3 Y115Y / / L10F,K20V 
4 
K70K,L100L,Q151Q,T215T, 
P225P,F227F 
/ V179F,M230W / 
5 K66K,P225P / E44A,K219N L33I 
6 K101K / K219K/X L10F,K20I 
7 
A62A,K101K,K103K,V179V, 
G190G,P225P 
/ / / 
8 A62A,K70K,F116F N88N / M36M/L 
9 G190G / / L10F 
10 D67D,L100L,Q161Q,P225P / K70S,A98S 
K20I,G73T, 
V82C 
11 L100L V32V 
A98A/S, 
V179I 
E35D 
12 L100L,Q161Q / / K20K/T 
Table 9.B.  Resistance sites . Time 2 
 Silent mutations Others mutations 
P RT PR RT PR 
1 L100L,P225P L24L V179I,F227N/I/Y/F L63A 
2 F77F,Q151Q / D67S 
K20I,L24F, 
L33I 
3 / / K219K/R K20V 
4 
K70K,L100L,Q151Q,H208H,
P225P,F227F 
H69H,L89L / E35D 
5 T69T,P225P / E44A,K219N E35N 
6 K101K,F227F L33L / K20I 
7 
A62A,K103K V179V G190G 
P225P 
/ / / 
8 F116F L33L,N88N K103R / 
9 G190G  / / 
10 D67D,L100L,Q161Q,P225P 
V11I,T12S,I15V,
Q18QP/E/A,S37D
,I62V,I72T,I93L 
K70S, 
A98S 
L33V,E34A, 
V82C 
11 L100 V32 A98A/S E35D 
12 L100L,Q161Q / / K20T 
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Table 10.A. Other mutations not evaluated in resistance report . Time 1. 
P RT Polymorphisms  PR Polymorphisms  
1 T39A,K43K/Q,I135M,I142T,D177N,V189I,I195L,G196R, L214F L23I,S37N,I62V,I64V,I93L 
2 
K43K/Q/X,K46K/R,S48P/L/S/F,V60I/V,S68S/G,Q91Q/X,E122K/E,D123E,R125R/S,Y127Y/F,A129A/V
,P133P/L,I135T/I,136N/Y,N137N/I,E138E/D,I142I/F,R143R/S/X/C,I178I/M,G196E/G,T200T/A, 
H208H/Y,R211K/R,L214F,V245E 
I15I/V,L33I/L,E35E/D,S37N,K55K/R,Q58Q/E, 
I62I/V,V77I/V 
3 K43Q,V111I,E122K,D123E,D177E,I178M,V189I,E203D,Q207E, H208Y,R211K,L214F 
W6X/S/W,I15V,E35D,S37D,Q61R,I72L,G73S, 
L76V,I85V 
4 
C38C/F,K43Q,K49R,E53K/E,V60I,D121Y,S134S/G,I135T,N136K/N,E138A/V,T139T/P,Q145Q/X, 
P150T/P,W153X/W/C,F160S, S163S/R,M164M/L,E169E/D,K173K/T,I178M,D185D/G,T200L, 
R206R/S,Q207G,R211K,L214F,T216T/S,D218E/D,Q222Q/X,E233E/X,H235Q/H,D237?,T240T/A 
Q7Q/H,I13I/L,I15V/L,Q18Q/E,D29D/V,S37N, 
G40E/G,R41K,V56R/S/I/G/V,D60E,Q61E,I62V, 
P79P/L,I85V,T91N/T,I93L 
5 
T39T/S,K43E,K46K/X,I50M/I/L/F,P52P/L,E53D,E122K/T,D123E,I132K/I,E138E/G,T139Q/P/E/A, 
R143T/R,L149L/V,D177E,E194A, G196E,R211K,L214F,V245E,L246P/L,P247? 
L5?,W6X/W,I13V,A22V,E34Q,E35N,S37D,D60E,
I62R/S/I/G/V,I72L,N83D,F99? 
6 
T39?,R83K,K102Q,E122K,D123E,I135L,E138G,P140Q/P,R143K/R,Q145K/Q,Y146X/Y,P150P/S, 
K173E,Q174Q/X,I178L,R206R/S/I,H208Y,R211K,L214F,K220K/I,Q222Q/H,K223K/I/X/L,H235H/L, 
K238K/I,I244K/I,V245E 
L33M/L,S37N,I62V,I72R,I85V,I93L 
7 
T39A,K43E,F61X/Y/L/F,R83K,L120L/F,E122K,A129A/V/S/L,I135K/I,Y144X/Y,P157P/R,T200A,L214F,
V245E 
V11I/F,I13I/L,I15V,L23I,T26T/I,E34Q,S37D, 
K43T,G51A,K55R,Q61Q/X,F99Y/F 
8 
C38G/V/C/F,E40E/D/V,K43K/N,R83K,V90I/V,F124N/I/Y/F,F130Y/F,S134R/S,Y144K/N/X/Y,L214F, 
E233E/D,L234P/L/S/F,H235N/H, W239X/W,V245E 
I151V,S37N,I72V 
9 T39A,D123E,I142V,K173Q,R211K,L214F,V245K 
L33F,E35D,S37N,R41K,I62V,H69K,T74P,I93M,F
99? 
10 
T39?,K49R,V60I,S68G,L92L/F,E122K,D123E,I135L,N137S,T165K/T,E169D,P170H,Q174Q,T200A, 
H208Y,R211K,L214F 
V11I,T12S/L,I13V,K14K/M,I15V,E35D,S37D, 
I62V,I72T,I93L 
11 
E40Q/E,K49K/R,V60I,R83K,E122K,I135T/I,N136K/N/T,E138E/A,S156S/L,S163S/R,M164M/I, 
T165T/A,Q174Q/R,D177D/G,Q182Q/P,D186D/Y,V189G/V,D192E/D,L193L/F,E194E/G,Q197Q/P, 
H198H/D,R199R/X/W,T200T/A,I202G/V,E204E/G,L205M/I/L, Q207Q/P,L209P/L,L214F 
S37N,K45K/R,I62V,I64I/V 
12 
C38?,K43K/Q,V60I,D123N,K166R,D177E,I178M/I,T200T,R211N/D,L214F,W239M,T240A,Q242R, 
V245E 
W6X/W,I13V,S37N,I62V,I64V,L76V 
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Table 10.B. Other mutations not evaluated in resistance report . Time 2. 
P Polymorphisms RT Polymorphisms PR 
1 
T39A,S105T,I135M/V,I142T,D177N,V189I,I195I/L,G196E,R206K/R,L214Y/F,D218E/D,E233K/E, 
D237D/A,W239X/W 
K14K/Y,L23I,S37N,K45K/R,I62V,I64V,I72V,T
91S, 
I93L 
2 
K43Q,D123E,I35T,V148G/V,V189I/V,G196E,R206R/M,Q207Q/L,H208Y,R211K,L214F,K220K/I, 
E224E/D,G231G/C,H235H/L,D237D/Y,V241V/L,V245E 
I15V,E35D,S37N,K55R,Q58E,I62V 
3 
E40E/D,K43Q,V111I,E122K,D123E,E138Q/E,G141G/W,I142N/I/H/L,D177E,I178I/M,V189I, 
E203N/D,R206R/I,Q207E, H208Y,R211K,L214F,V245G/V, 
I15L/V,Q18Q/H,E34Q,E35D,S37D,R57K/R,Q6
1R, 
I62V,I72L,L76V,I85V 
4 
K43K/Q/E,K49R,V60I,D121Y,T131T/A,I135T,N137N/Y,E138A,S156S/L,K166R,I178M,T200L,Q207G,
R211K, L214F,Q222Q/H,P226P/L/S,L228R,K238N,V245E 
I15V,S37N,R41K,D60E,Q61E,I62V,I85V,I93L,
T96T/I 
5 
E42E/G,K43E,E53D,D121H,T139A,I142I/F,R143R/I/G/V,P157P/S,D177E,E194A,G196E,R206R/S/I, 
R211K,L214F,V241E/V,V245E 
K14K/X,A22V,S37D,K55R,D60E,I62V,I72L,T9
1S, 
Q92Q/E,F99? 
6 
K49K/N,R83K,K102Q,E122K,D123E,A129T/A,I135I/L,E138G,K173E,I178L,H208Y,R211K,L214F, 
L228?, W229R/W,Y232N/Y,E233K/E,L234N/I/H/L,H235N/H,D237N/D,V241E/V,I244K/I,V245K/E 
S37N,I62V,I72R,I85V,I93L 
7 
T39A,K43E,S48S/L,P52P/L,R83K/R,E122K,F124I/F,A129E/A,F130Y/F,P133H/P,S134R/S,V148M/V, 
T200A, R211K/R,L214F,Q242Q/L,P243P/L,V245K/E 
W6G/W,L23I,E34Q,S37D,K43T,G51A,K55R 
8 
T39T/S,E40K/E,S48S/L,R83K,N136K/N/T,E138D/E,P140Q/P,T200A,R206R/I,L214F,D218D/Y, 
H221H/L, Q222Q/H,K223K/I/X/L, P226P/S,K238K/I/M,I244K/I,V245E 
K14K/M,I15R/I,G16A,T26T/S,S37N,I72V,I93
N/I,G94G/W/C,C95C/W/F/L,L97L/F,N98K/N 
9 T39A,D123E,I142V,P157P/R,K173Q,R211K,L214F,V245K 
T12T/I,I15I/V,E35D,S37N,R41K,I62V,H69K,T
74P, 
I93M 
10 
T39A,K49R,V60I,S68G,V111I,E122K,D123E,I135L,N137S,I142I/F,R143R/I,W153G/X/W,G155E/G, 
E169D, P170H,I178L,T200A,I202I/V,R211K,L214F,L228R,D237E,V245E/V 
V11I,T12S,I15V,Q18QP/E/A,S37D,I62V,I72T,
I93L 
11 
C38F,T39?,E40E/D/G/V,K49R,N57K/N,V60I,R83K,E122K,I132T/I,P133H/P,S134N/S,T139T/R, 
K154K/E, G155R/G,Q174Q/R,T200T/A,I202V,L214F,L228H/L 
S37N,K45R,I62V,I64V,N98N/I 
12 
K43K/R,V60I,K82K/R,R83K/R,D123N,I135T,Q145Q/H/X/Y,K166R,D177E,I178L/F,R211N/D,L214F, 
D218E, I244K/I,V245T 
I13V,S37N,I62V,I64V,L76V 
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Table 11.A. New interpretation of resistance mutations. Time 1. 
P NRTI mutations NNRTI mutations  PI  mutations 
1 M41L, Q161Q/L,T215Y K103N, Y188L 
L10I, K20R, M36I, M46L, G48V, I54V, I62V, 
A71V, V82S, L90M, I93L 
2 
E44D, A62V, K65R, L74V, V75I, 
M184V, L210W, T215S/Y 
V118I, H208H/Y 
L10I/L, I15I/V,K20K/I/M, L33I/L, M36I/M, 
M46I/M, F53L/F, I54I/V, Q58Q/E, I62I/V,L63P, 
A71A/V, G73S/G, V82A/V, L90M/L 
3 
M41L, E44K/N/E/D, D67N, 
L210W, T215Y 
H208Y 
L10F, I15V, K20V, M46I, I54L, L63P, G73S, L76V, 
I84V, I85V, L90M 
4 M41L, L210W 
K101E,Y181C, 
G190A 
L10F, K20M, L24I, M36I, M46I, I54V, D60E, I62V, 
L63P, A71V, V82A, I85V, I93L 
5 M41L, D67N, L210W, T215Y V118I 
L10F, I13V, K20R, L24I, L33I, E34Q, M36I, M46I, 
D60E, I62R/S/I/G/V, L63P, A71V, G73S, V82A, 
N83D, I84V 
6 M41L, D67N, L210W, T215Y H208Y 
L10F, K20I, M36I/M, M46I, I47I/V, I54V, I62V, 
L63P, A71V, G73S, I84V, I85V, L90M, I93L 
7 
M41L, D67N, M184V, L210W, 
T215Y 
V118I 
L10I, V11I/F, I15V, L33F, E34Q, K43T, M46I, 
F53L, L63P, A71V, G73S, V82A, L90M 
8 / / M36M/L, L63P 
9 M41L, M184V, L210W, T215Y V118I 
L10F, K20R, D30N, L33F, M36I, I54V, I62V, L63P, 
H69K, A71V, T74P, I84V, L90M, I93M/L 
10 F116Y, Q151M, T215D H208Y 
L10I, V11I, I13V, I15V, K20I, M36I, M46I, I54V, 
I62V, L63P, A71T, G73T, L90M, I93L 
11 
D67N, K70R, M184V, T215F, 
K219Q 
/ 
K20K/R, M36I, M46L, I50L, I62V, L63P, A71V, 
G73S, L90M 
12 
M41L, E44D, D67N, M184V, 
L210W, T215Y 
V118I 
L10I, I13V, K20K/T, M46I, I54I/L, I62V, L63P, 
L76V, I84V 
 
Table 11.B. New interpretation of resistance mutations. Time 2. 
P NRTI mutations NNRTI mutations  PI  mutations 
1 
M41L, K65K/R, D67N/D, 
Y115Y/F, M184V, T215Y 
K103N, Y188L 
L10I, K20R, M36I, M46L, G48V, I54V, I62V, 
A71V, V82S, L90M, I93L 
2 
M41L, E44D, A62V, L74V,  
L210W, T215Y 
K101K/E,V118I,Y18
1C,G190S,H208Y 
L10I, I15V, K20I, L33I, M36I, M46I, F53L/F, 
I54V, Q58E, I62V, L63P, A71V, G73S, V82A, 
L90M 
3 
M41L, D67N, M184V, L210W, 
T215Y, K219K/R 
K103N, H208Y 
L10F, I15L/V, K20V, E34Q, M36I, M46I, I54L, 
I62V, L63P, A71V, G73T/S, L76V,I84V, I85V, 
L90M 
4 M41L, L210W, T215Y 
K101E, V118I, 
Y181C, G190A 
L10I, K20M, L24I, M36V, M46I, F53L/F, I54V, 
D60E, I62V, L63P, A71V, V82A, I85V, I93L 
5 M41L, D67N, L210W, T215Y V118I 
L10F, I13V, K20R, L24I, L33I, E34Q, M36I, M46I, 
D60E, I62V, L63P, A71V, G73T, V82A, N83D, 
I84V 
6 
M41L, E44E/D, D67N/D, M184V, 
L210W, T215Y/C 
K103N, V108I, 
H208Y 
L10F, K20I, M36I, M46I, I62V, L63P, A71V, G73S, 
I84V, I85V, L90M, I93L 
7 
M41L, D67N, M184V, L210W, 
T215Y 
V118I 
L10I, L33F, E34Q, K43T, M46I, F53L, I54V, L63P, 
A71V, G73S, V82A, L90M 
8 M184V, T215Y / L63P, L90M/L 
9 M41L, L210W, T215Y 
L100I, K103N, 
V118I 
I15I/V, K20R, M36I, M46L, I54V, I62V, L63P, 
H69K, A71I, T74P, I84V, L90M 
10 
Y115F, F116Y, Q151M, M184V, 
T215D 
K103S, Y188H, 
H208Y 
L10I, V11I, I13V,I15V, K20I, L33V, M36I, M46I, 
I54V, I62V, L63P, A71T, G73T, I84V, L90M, I93L 
11 D67N, K70R, T215F, K219Q 
K103N, Y181C, 
P225H/P 
M36I, M46L, I50L, I62V, L63P, A71V, G73S, L90M 
12 
M41L, E44D, D67N, V75M, 
M184V, L210W, T215Y, K219Q 
V118I, G190S L10I, I13V, K20K/T, M46I, I62V, L63P,L76V, I84V 
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 With the new interpretation it has been possible to determine that 
in all patients several resistance mutations (in red in the table) toward 
PI appear in both new reports, that mutations seen in the first 
interpretation as polymorphisms in sites of non-resistance, or neutral 
mutations in resistance sites, while as far as transcriptase mutations is 
concerned, only in some patients we observed other resistance 
mutations, the more frequent being the  H208Y. 
   
 This mutations discordance caused a few differences in the drug-
resistance interpretation. 
The amino acid substitutions that confer resistance to the principal 
drugs in use, considered by latest library (g12) of OpenGene DNA 
System Software, updated at 2006, are listed in table 6. Some 
mutations are associated to resistance toward both NRTI and NNRTI. 
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Table 6. Resistance mutations considered by library G12 
NUCLEOSIDE  
RT INHIBITORS  
NON NUCLEOSIDE  
RT INHIBITORS  
PROTEASE  
INHIBITORS  
 
Abacavir (ABC) 
Didanosine (ddl) 
Lamivudine (3TC)/ 
Emtricitabine (FTC) 
Stavudine (d4T) 
Tenofovir (TDF) 
Zidovudine (AZT) 
 
 
Efavirenz (EFV) 
Nevirapine (NVP) 
 
 
Amprenavir (APV)/Fosamprenavir 
(FPV) 
Atazanavir (ATV) 
Indinavir (IDV) 
Lopinavir + Ritonavir (LPV/r) 
Atazanavir + Ritonavir (ATV/r) 
Nelfinavir (NFV) 
Saquinavir + Ritonavir (SQV/r) 
Tipranavir + Ritonavir (TPV/r) 
Darunavir + Ritonavir (DRV/r) 
associated mutations 
 
M41L 
E44D 
A62V 
K65R 
D67N 
T69D/N 
T69XX/XXX/XXXX* 
K70R/E 
L74V 
V75A/I/M/S/T 
F77L 
W88G 
Y115F 
F116Y 
V118I 
Q151M 
Q161L 
Y181C 
M184I/V 
L210W 
T215C/D/F/S/V/Y 
K219E/Q/R 
 
associated mutations 
 
A98G 
L100I 
K101E/P/Q 
K103H/N/S/T 
V106A/M 
V108I 
V118I 
V179D/E 
Y181C/I 
Y188C/H/L 
G190A/E/S 
H208Y 
P225H 
F227L 
M230L 
 
 
 
 
 
associated mutations 
 
L10F/I/M/R/V 
V11I 
I13V 
I15A/V 
G16E 
K20I/M/R/T/V 
L24I/V 
D30N 
V32I 
L33F/I/V 
E34Q 
E35G 
M36I/L/V 
K43T 
M46I/L/V 
I47A/V 
G48M/V 
I50L/V 
F53L 
I54A/L/M/S/T/V 
Q58E 
D60E 
I62V 
L63P/T 
H69K 
A71I/L/T/V 
G73A/C/S/T 
T74P/S 
L76V 
V77I 
V82A/F/L/M/S/T 
N83D 
I84A/C/V 
I85V 
N88D/S 
L89I/M/V 
L90M 
I93L 
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Drug-susceptibility of first report and latest interpretation are shown in 
table 12. 
 The major discordances between the two interpretations have been 
observed in the first test, as expected based on previous poorer 
information about the HIV resistance mechanisms. The most diverse 
drugs were within NRTIs, stavudine (d4T)  and tenofovir (TDF) (Figure 
3). The total number of non-responder patients except one at time 1 
were in therapy with d4T or TDF. No discordances with new 
interpretation were noted for NNRTIs. 
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Table 12. Double interpretation of resistance tests for each patient 
1° TEST 
P NRTI  NNRTI  PI 
 AZT ddI 3TC/FTC d4T ABC TDF  NVP EFV  SQV IDV NFV APV/FAPV LPV/r ATV TPV/r 
1                                   
2                                   
3                                   
4                                   
5                                 
6                                 
7                                 
8                                 
9                                 
10                                 
11                                 
12                                   
                  
2° TEST 
P NRTI  NNRTI  PI 
 AZT ddI 3TC/FTC d4T ABC TDF  NVP EFV  SQV IDV NFV APV/FAPV LPV/r ATV TPV/r 
1                                 
2                                 
3                                 
4                                 
5                                 
6                                 
7                                 
8                                 
9                                 
10                                 
11                                 
12                                 
                                 
Red= Resistance, Yellow= Possible resistance, Green= No evidence of resistance 
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Figure 3. Drugs with more discordances of interpretation 
 
 
 
 
 
 
 
 
 
 
 
 
 At the state of art, the laboratory informations collected were 
compared with the clinical history of each patient and their therapeutic 
regimen, in order to understand if a different interpretation of the test 
performed could have lead to a different therapeutic choice. 
The interpretation of genotipic test act to detect drug resistance 
wouldn’t have been as effective as expected in order to choose a better 
therapy, mainly due to the personal individual differences present in a 
so dishomogeneous choort of patients, and in particolar because of the 
poor availability of effective drugs at that time. 
This is confirmed by the fact that most of these patients are right now 
positively responding to drugs of the new generation.  
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Discussion 
 
 HIV drug resistance is a complicated and dynamic topic. 
Considerable new information on the epidemiology, pathogenesis, and 
clinical significance of HIV-1 drug resistance and resistance testing was 
published during the last years.  
 In fact, genotyping analysis during the course of antiretroviral 
treatment might provide significant informations that should be 
carefully considered as guidelines for rational therapeutic strategies.  
 Despite considerable progress, much remains to be learned about 
antiretroviral drug resistance.  
Treatment of advanced HIV infection is usually characterized by an 
extensive resistance to all available classes of treatment.  
 The availability of new drugs and the understanding of treatment 
principles that have engendered in these patients a greater success 
than in years past mean that the prospects for such patients have never 
been brighter. It is likely that additional new drugs and greater 
understanding of proper management strategies will continue to 
characterize future management approaches. 
Nevertheless, a more profound understanding of genotypic data could 
allow significant improvements in the management of HIV infection with 
the current arsenal of antiretroviral drug. 
 The genotypic analysis is generally limited to the amino acid 
positions that are known to be involved in drug resistance, while an 
analysis of the complete amino acid sequences may yield to a wider 
amount of informations, e.g. on new putative resistance-associated 
amino acid positions. 
 
In this study we tried to evaluate if a more complete resistance report 
will improve the strategy of the therapeutic choice for these complex 
patients. 
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Some of the informations not included in the report might be more 
useful than what expected if better analyzed, and more clearly 
pondered at the moment of the therapeutic choice, even if they seems 
have no evidence of resistance. 
  This kind of approach requires a deep and update knowledge of the 
last discovery about the drug resistance, and a wider experience of the 
physicians. 
 The limit of our study is the small number of patients analyzed, and 
the fact that this is a dishomogeneous group for what concern the 
characteristics analyzed, if not the presence of multiple therapeutic 
failure.   
 Much more is to know about drug resistance than the canonical 
mutations identified. Anyway, we can conclude that our study added 
additional knowledge on the genotypic test role to provide a useful 
resistance report.   
 We are aware of the difficult for the physicians to keep themselves 
update on all the new informations coming out daily in this field, but we 
recognize the necessity of it to a better management of so difficult 
patients.  
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